MX2022003845A - Tratamientos cognitivos medicinales. - Google Patents

Tratamientos cognitivos medicinales.

Info

Publication number
MX2022003845A
MX2022003845A MX2022003845A MX2022003845A MX2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A MX 2022003845 A MX2022003845 A MX 2022003845A
Authority
MX
Mexico
Prior art keywords
medicinal
healthy subject
cognitive
treatments
cognitively healthy
Prior art date
Application number
MX2022003845A
Other languages
English (en)
Spanish (es)
Inventor
Tamara Diane Miller
John William Ketelbey
Original Assignee
Actinogen Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019903681A external-priority patent/AU2019903681A0/en
Application filed by Actinogen Medical Ltd filed Critical Actinogen Medical Ltd
Publication of MX2022003845A publication Critical patent/MX2022003845A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2022003845A 2019-09-30 2020-09-30 Tratamientos cognitivos medicinales. MX2022003845A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2019903681A AU2019903681A0 (en) 2019-09-30 Medicinal cognitive treatments
PCT/AU2020/051043 WO2021062472A1 (en) 2019-09-30 2020-09-30 Medicinal cognitive treatments

Publications (1)

Publication Number Publication Date
MX2022003845A true MX2022003845A (es) 2022-06-22

Family

ID=75336310

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022003845A MX2022003845A (es) 2019-09-30 2020-09-30 Tratamientos cognitivos medicinales.

Country Status (10)

Country Link
US (1) US20230000843A1 (https=)
EP (1) EP4037684A4 (https=)
JP (1) JP2022550221A (https=)
KR (1) KR20220080116A (https=)
CN (1) CN114761005A (https=)
CA (1) CA3152902A1 (https=)
CL (1) CL2022000781A1 (https=)
IL (1) IL292739B1 (https=)
MX (1) MX2022003845A (https=)
WO (1) WO2021062472A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202523658A (zh) * 2019-05-24 2025-06-16 美商賽吉醫療公司 化合物、組合物及使用方法
WO2022115620A1 (en) * 2020-11-25 2022-06-02 Sage Therapeutics, Inc. 4-fluoro-(4-(4-benzyl)piperidin-1-yl)(2-(pyrimidin-4-yl)pyridin-3-yl)methanone derivatives and similar compounds as cyp46a1 inhibitors for the treatment of neurodegenerative disorders
CN120153257A (zh) * 2022-10-07 2025-06-13 射线质医疗有限公司 用于11β-HSD1抑制剂治疗的受试者选择
WO2025073002A1 (en) * 2023-10-03 2025-04-10 Actinogen Medical Limited Tablet formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8642621B2 (en) * 2009-09-16 2014-02-04 The University Of Edinburgh (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds and their use
AU2011247116B2 (en) * 2010-04-29 2015-12-03 The University Of Edinburgh 3, 3 -disubstituted- ( 8 - aza - bicyclo [3.2.1] oct- 8 - yl) -[5- (1H - pyrazol - 4 -yl) -thiophen-3 -yl] methanones as inhibitors of 11 (beta) -HSD1

Also Published As

Publication number Publication date
WO2021062472A1 (en) 2021-04-08
KR20220080116A (ko) 2022-06-14
CN114761005A (zh) 2022-07-15
IL292739B1 (en) 2026-04-01
AU2020359291A1 (en) 2022-04-21
IL292739A (en) 2022-07-01
EP4037684A4 (en) 2023-11-01
CA3152902A1 (en) 2021-04-08
EP4037684A1 (en) 2022-08-10
US20230000843A1 (en) 2023-01-05
JP2022550221A (ja) 2022-11-30
CL2022000781A1 (es) 2022-11-18

Similar Documents

Publication Publication Date Title
MX2022003845A (es) Tratamientos cognitivos medicinales.
ZA202109010B (en) Compounds and methods for the treatment of covid-19
BR112022000019A2 (pt) Composto da fórmula, composição farmacêutica e método de tratamento de câncer
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
ECSP22089498A (es) Inhibidores de il4i1 y métodos de uso
PH12021550713A1 (en) Medicament for the treatment of chronic cough
JOP20190086A1 (ar) مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
PH12023550780A1 (en) Line-1 inhibitors to treat disease
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
CL2021003303A1 (es) Tratamiento para sinucleinopatías.
WO2020128614A8 (en) Method for treating interstital lung disease
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.
MX2021002590A (es) Metodos de uso de un compuesto de fenoxipropilamina para tratar el dolor.
JOP20210221A1 (ar) علاجات مشتركة لاستخدامها في علاج السرطان
AR126393A1 (es) Terapia combinada para el tratamiento de enfermedades hepáticas
MX2023009620A (es) Metodos terapeuticos.
BR112022005980A2 (pt) Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto
PH12020551620A1 (en) Compositions for preventing or treating dry eye
GEAP202316350A (en) Treatments of prader-willi syndrome
CL2025000332A1 (es) Tratamiento de la urticaria con inhibidores de jak.
JOP20240263A1 (ar) مثبطات ripk1 وطرق الاستخدام